What’s behind the enormous increase in early-onset gastrointestinal cancers?
Peer-Reviewed Publication
Updates every hour. Last Updated: 13-Sep-2025 00:11 ET (13-Sep-2025 04:11 GMT/UTC)
A new paper in BJS, published by Oxford University Press, indicates that early-onset gastrointestinal cancer rates are rising dramatically across the globe.
Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers a roadmap for designing safer, more targeted therapies.
The WEHI-led discovery, published in Science, has uncovered a critical new role for MCL-1, revealing it not only prevents cell death but also provides cells with the energy they need to function.
The findings reshape our understanding of how cells survive and thrive, with implications for both cancer treatment and developmental biology.
Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase Cancer Center scientist helps explain why — and offers three strategies for making treatment more effective.